FDA Cites Imaging Drug Web Sites, Draws "Respectful" Disagreement
This article was originally published in The Gray Sheet
Executive Summary
Bracco Diagnostics took down a promotional Web site recently, under protest, to comply with a request from FDA's Division of Drug Marketing, Advertising and Communications that it stop making "false and unsubstantiated claims" for its contrast media agent Isovue (iopamidol-370)
You may also be interested in...
Social Media Promotion Guidance Requested, But Won't Be Out Soon
Medical products companies are asking for more guidance from both FDA and from trade organizations on best practices for Internet marketing and promotion using social media tools
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.